Literature DB >> 7665622

Inhibition of nucleotide excision repair by the cyclin-dependent kinase inhibitor p21.

Z Q Pan1, J T Reardon, L Li, H Flores-Rozas, R Legerski, A Sancar, J Hurwitz.   

Abstract

p21, a p53-induced gene product that blocks cell cycle progression at the G1 phase, interacts with both cyclin-dependent kinases and proliferating cell nuclear antigen (PCNA). PCNA functions as a processivity factor for DNA polymerases delta and epsilon and is required for both DNA replication and nucleotide excision repair. Previous studies have shown that p21 inhibits simian virus 40 (SV40) DNA replication in HeLa cell extracts by interacting with PCNA. In this report we show that p21 blocks nucleotide excision repair of DNA that has been damaged by either ultraviolet radiation or alkylating agents, and that this inhibition can be reversed following addition of PCNA. We have determined that p21 is more effective in blocking DNA resynthesis than in inhibiting the excision step. We further show that a peptide derived from the carboxyl terminus of p21, which specifically interacts with PCNA, inhibits polymerase delta-catalyzed elongation of DNA chains almost stoichiometrically relative to the concentration of PCNA. When added at higher levels, this peptide also blocks both SV40 DNA replication and nucleotide excision repair in HeLa cell extracts. These results indicate that p21 interferes with the function of PCNA in both in vitro DNA replication and nucleotide excision repair.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7665622     DOI: 10.1074/jbc.270.37.22008

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  44 in total

Review 1.  The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer.

Authors:  Katrien Vermeulen; Dirk R Van Bockstaele; Zwi N Berneman
Journal:  Cell Prolif       Date:  2003-06       Impact factor: 6.831

2.  Isolation and characterization of two human transcription factor IIH (TFIIH)-related complexes: ERCC2/CAK and TFIIH.

Authors:  J T Reardon; H Ge; E Gibbs; A Sancar; J Hurwitz; Z Q Pan
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

Review 3.  Multiple functions of p21 in cancer radiotherapy.

Authors:  Yanbei Kuang; Jian Kang; Hongbin Li; Bingtao Liu; Xueshan Zhao; Linying Li; Xiaodong Jin; Qiang Li
Journal:  J Cancer Res Clin Oncol       Date:  2021-02-05       Impact factor: 4.553

4.  Mutations in yeast proliferating cell nuclear antigen define distinct sites for interaction with DNA polymerase delta and DNA polymerase epsilon.

Authors:  J C Eissenberg; R Ayyagari; X V Gomes; P M Burgers
Journal:  Mol Cell Biol       Date:  1997-11       Impact factor: 4.272

Review 5.  Cell penetrating elastin-like polypeptides for therapeutic peptide delivery.

Authors:  Gene L Bidwell; Drazen Raucher
Journal:  Adv Drug Deliv Rev       Date:  2010-05-15       Impact factor: 15.470

6.  Arsenic Inhibits DNA Mismatch Repair by Promoting EGFR Expression and PCNA Phosphorylation.

Authors:  Dan Tong; Janice Ortega; Christine Kim; Jian Huang; Liya Gu; Guo-Min Li
Journal:  J Biol Chem       Date:  2015-04-23       Impact factor: 5.157

7.  Nucleotide excision repair in the third kingdom.

Authors:  M Ogrünç; D F Becker; S W Ragsdale; A Sancar
Journal:  J Bacteriol       Date:  1998-11       Impact factor: 3.490

Review 8.  Regulation of DNA damage response pathways by the cullin-RING ubiquitin ligases.

Authors:  Jeffrey Hannah; Pengbo Zhou
Journal:  DNA Repair (Amst)       Date:  2009-02-23

9.  Analysis of genomic instability in Li-Fraumeni fibroblasts with germline p53 mutations.

Authors:  P K Liu; E Kraus; T A Wu; L C Strong; M A Tainsky
Journal:  Oncogene       Date:  1996-06-06       Impact factor: 9.867

10.  Serine 123 phosphorylation modulates p21 protein stability and activity by suppressing ubiquitin-independent proteasomal degradation.

Authors:  Xiangling Chen; Jin Zhang; Min Zhang; Shou Liu; Wensheng Yan; JinHyuk Jung; Xinbin Chen
Journal:  J Biol Chem       Date:  2012-08-20       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.